Why the study?
Does heparin alter digitoxin protein binding in vivo in hemodialysis patients on digitoxin maintenance therapy?
Does heparin alter digitoxin protein binding in vivo in hemodialysis patients on digitoxin maintenance therapy?
Heparin does not alter digitoxin protein binding in vivo; previously reported reductions in binding are artifacts of heparin-induced in vitro lipolysis.
Answers are grounded in this paper and cite their sources.
Findings support no heparin effect on digitoxin binding in hemodialysis patients; challenges earlier reports as in vitro artifacts.
Reduction of digitoxin binding to plasma proteins after heparin has been reported. Our aim was to determine whether this reduction is an in vivo effect or occurs only after blood collection as a result of heparin-induced lipolysis that increases levels of nonesterified fatty acids in vitro. The effect of heparin on digitoxin protein binding was studied in 10 patients undergoing hemodialysis receiving digitoxin maintenance therapy. Digitoxin free fraction increased after heparin, from 2.5% +/- 0.7% to 4.4% +/- 1.1%, but after inhibition of in vitro lipolysis with diethyl p-nitrophenyl phosphate (2mM), a potent lipase inhibitor, there was no increase in the free fraction (2.3% +/- 0.4% before heparin and 2.4% +/- 0.5% after heparin). Digitoxin salivary levels were also unchanged (0.41 +/- 0.08 ng/ml before heparin and 0.41 +/- 0.08 ng/ml after heparin [n = 8]). These data indicate that the binding of digitoxin to plasma proteins in vivo is not altered by heparin. The reduced binding reported elsewhere was a result of heparin-induced in vitro lipolysis.
No takes yet. Share an insight, caveat, or question.
Lohman et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: